1235318-89-4

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Pyrimidinamine, 4-Methyl-N-[5-Methyl-4-(1H-pyrazol-4-yl)-2-thiazolyl]is used as a key intermediate in the synthesis of potential drug candidates. Its unique chemical structure and properties contribute to the development of new therapeutic agents with improved efficacy and safety profiles.
Used in Medicinal Chemistry:
2-PyriMidinaMine,4-Methyl-N-[5-Methyl-4-(1H-pyrazol-4-yl)-2-thiazolyl]is used as a target for study in the field of medicinal chemistry. Its potential biological and pharmacological activities make it a promising candidate for the discovery of novel therapeutic agents with diverse applications.
Used in the Treatment and Management of Medical Conditions:
2-Pyrimidinamine, 4-Methyl-N-[5-Methyl-4-(1H-pyrazol-4-yl)-2-thiazolyl]may have applications in the treatment and management of various medical conditions. Its potential therapeutic effects are currently being explored in preclinical and clinical research to determine its suitability for specific indications.

Upstream product

• 1235313-79-7 4-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-5-methylthiazol-2-amine 
• 130645-48-6 2-bromo-4-methyl-pyrimidine 

Relevant academic research and scientific papers

Radiosynthesis and evaluation of 5-methyl-N-(4-[11C]methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)thiazol-2-amine ([11C]ADX88178) as a novel radioligand for imaging of metabotropic glutamate receptor subtype 4 (mGluR4)

ADX88178 (1) has been recently developed as a potent positive allosteric modulator for metabotropic glutamate receptor 4 (mGluR4). The aim of this study was to develop [11C]1 as a novel positron emission tomography ligand and to evaluate its bi

NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of Formula (I), wherein M, P, A and (B)n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ( mGluR4 ) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.